abiraterone acetate, Janssen Biotech, MAGNITUDE, mCRPC, Niraparib
Niraparib and abiraterone acetate plus prednisone is approved by FDA for BRCA-mutated metastatic castration-resistant prostate cancer
August 2023: The fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), along with prednisone, has been approved by the Food and Drug Administration for adult patients with castration-resista..
Bayer HealthCare Pharmaceuticals Inc, Darolutamide, docetaxel, Nubeqa
Darolutamide tablets is approved by FDA for metastatic hormone-sensitive prostate cancer
August 2022: Darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets combined with docetaxel were approved by the Food and Drug Administration for adult patients with metastatic hormone-sensitive prostate cancer (mHS..
gallium Ga 68 gozetotide, Locametz, lutetium Lu 177 vipivotide tetraxetan, mCRPC, Novartis, Pluvicto, PSMA
Pluvicto is approved by FDA for metastatic castration-resistant prostate cancer
April 2022: The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patients with prostate-specific mem..
Doppler, ED, erectile dysfunction, HIFU, HIFU beam, High Intensity Focused Ultrasound, prostate cells
High Intensity Focused Ultrasound
March 2022: HIFU (High Intensity Focused Ultrasound) is a cutting-edge therapy that uses focused, high-energy ultrasound waves to heat and kill cancerous parts of the prostate gland. The target tissue is heated to 880 to 980 degre..
GnRH, HERO, Myovant Sciences, oral gonadotropin-releasing hormone, ORGOVYX, receptor antagonist, relugolix
The FDA has approved relugolix for the treatment of advanced prostate cancer
August 2021: The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix (ORGOVYX, Myovant Sciences, Inc.), was approved by the Food and Drug Administration on December 18, 2020, for adult patients with met..